225 related articles for article (PubMed ID: 8289665)
1. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
Hvidberg A; Nielsen MT; Hilsted J; Orskov C; Holst JJ
Metabolism; 1994 Jan; 43(1):104-8. PubMed ID: 8289665
[TBL] [Abstract][Full Text] [Related]
2. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
3. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
4. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
7. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
8. Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs.
Freyse EJ; Becher T; El-Hag O; Knospe S; Göke B; Fischer U
Diabetes; 1997 May; 46(5):824-8. PubMed ID: 9133550
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
11. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
Schjoldager BT; Mortensen PE; Christiansen J; Orskov C; Holst JJ
Dig Dis Sci; 1989 May; 34(5):703-8. PubMed ID: 2714145
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
15. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
[TBL] [Abstract][Full Text] [Related]
16. Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.
Juhl CB; Schmitz O; Pincus S; Holst JJ; Veldhuis J; Pørksen N
Diabetologia; 2000 May; 43(5):583-8. PubMed ID: 10855533
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
18. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
19. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.
Dardevet D; Moore MC; Neal D; DiCostanzo CA; Snead W; Cherrington AD
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E75-81. PubMed ID: 15026303
[TBL] [Abstract][Full Text] [Related]
20. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
